DMTRF
3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | 14.69 | $3.5B | — |
| 2026 Q3 | 5.31 | $2.5B | — |
| 2025 Q2 | 8.00 | $2.6B | — |
| 2025 Q1 | 0.05 | $2.2B | $0 |
| 2025 Q4 | -11.00 | $1.9B | $0 |
| 2025 Q3 | -5.65 | $1.8B | $0 |
| 2024 Q2 | -0.18 | $1.8B | $0 |
| 2024 Q1 | -9.20 | $1.5B | $0 |